Pfizer Independent Medical
Education RFP
Diagnosis and Risk Factors forInvasive Mold Infections
Competitive Grant Program –Pfizer Internal Review Process

Overview
This competitive program seeks to encourage organizations tosubmit grant applications for independent educational activities
for health care professionals involved in the diagnosis andmanagement of patients with invasive fungal infections (IFI).

Geographic Scope
Global excluding United States

Project Types and Area of Interest
Potential applicants are encouraged to address theeducational needs of healthcare professionals relating to early
diagnosis of invasive mold and yeast infections to improve themanagement of patients with IFI. This can include:•Needs assessment to better understand, assess andidentify knowledge gaps and opportunities for action indiagnosis and testing including understanding of riskfactors.

•Educational tools/resources to reduce information barriers
and knowledge acquisition.

•Educational programs to improve knowledge
comprehension and ensure equitable access and improved
patient outcomes.

Key Milestones•

Application submission deadline: September 22, 2024•

Anticipated decision notification date: November 2024•

Anticipated project start date: January 2025

Funding Range
Individual projects requesting up to $75,000 USD will beconsidered. Pfizer anticipates awarding 5 projects.

I. Eligibility
Geographic Scope:•

Global excluding United States

Applicant Eligibility Criteria•

•

•

•

•
•
•

Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., anindependent group of physicians not affiliated with a hospital, academic institution, or professionalsociety).
The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools;
healthcare institutions (both large and small); professional associations and medical societies; medicaleducation companies; and other entities with a mission related to healthcare professional education
and/or healthcare improvement.
If the project involves multiple departments within an institution and/or between different institutions /organizations / associations, all institutions must have a relevant role and the requesting organizationmust have a key role in the project.
If the project involves multiple departments within an institution and/or between different institutions/organizations / associations, all institutions must have a relevant role and the requesting organizationmust have a key role in the project.
The applicant must be the project/program lead or an authorized designee of such individual (e.g.,project/program lead’s grant coordinator).
The project/program lead must be an employee or contractor of the requesting organization.
Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We
strongly recommend that applicants confirm this with their organization or institution prior to submitting anapplication. Grants awarded to organizations that are subsequently found to be unable to accept funding
directly from Pfizer Inc. may be subject to rescission.

II. Requirements
Date RFP Issued•August 8, 2024

Clinical Area•

Invasive Fungal Infections

General Area of Interest for this RFP:
Invasive fungal diseases and antifungal resistance are important global health issues that impact
vulnerable populations globally. In many settings, health care workers are unfamiliar with fungal
infections, which results in low clinical suspicion, misdiagnosis, incorrect or delayed treatment and often
poor patient outcomes.1
The intent of this RFP is to support independent medical education initiatives for health care professionals
involved in the management of patients with invasive fungal infections (IFI). Proposals that will beconsidered for Pfizer support will focus on:•Increasing the understanding of early diagnosis of invasive yeasts and mold infections to improvethe management of patients with IFI.

2

•

•

Addressing knowledge gaps in the testing, including laboratory capacity to detect fungal
resistance diagnosis, and early treatment of IFI and ensuring equitable access to such testing,that might also improve patient outcomes.
Increasing the understanding of the risk factors associated with IFI to better equip physicians to:• suspect a potential mold infection• diagnose the presence of an IFI based on clinical signs, symptoms, and risk factors• deploy appropriate diagnostic tests to confirm the type of infection

Successful proposals should include measurement of outcomes, inclusive of learner progression
throughout the activity, extent to which the activity closed the identified gaps, and patient impact.
It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeuticor diagnostic agents will not be considered.

Target Audience•Infectious Disease (ID) physicians, clinical microbiologists/mycologists, Intensive Care Unit (ICU)
physicians, onco- hematologists, internal medicine physicians, and other HCPs involved in the diagnosis
and treatment of patients with IFI.

Expected Approximate Monetary Range of Grant Applications:•Individual projects requesting up to $75,000 will be considered. Pfizer anticipates awarding 5 projects.

Key Dates:•••••

RFP release date: August 8, 2024
Grant Application due date: September 22, 2024
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
Anticipated Grant Award Notification Date: November 2024
Grants will be distributed following a fully executed agreement.
Anticipated Project Start Date: January 2025

How to Submit:•Note: Please read this section carefully since applications submitted not following these instructions will
not be accepted and will be cancelled
Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click “Create
your password”. [Note: there are individual portals for each grant application type. Please be sure to use the URLabove.]••

Click the “Start A New Knowledge Gap Application" button.
In the application:• For the question “What type of request are you submitting?” select Response to a Request for
Proposal (RFP)• For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive
Grant Program?” select Yes• Select the following Competitive Grant Program Name: 2024 HOS Global Invasive Fungal
Infections IME• Select the following Primary Area of Interest: Infectious Disease – Fungal - KG

3••Requirements for submission:
Complete all required sections of the online application and upload your project proposal (see Appendix)
in the General RFP Submission field.
If you encounter any technical difficulties with the website, please click the “Technical Questions” link atthe bottom of the page.
IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Talita
Honorato-Rzeszewicz at Talita.Honorato-Rzeszewicz@pfizer.com, with the subject line “2024 HOS
Global Invasive Fungal Infections IME.”

Grant Agreements:•••••

If your grant is approved, your institution will be required to enter into a written grant agreement withPfizer. Please click here to view the core terms of the agreement.
Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goalsof both parties. Negotiating grant agreements requires significant resources, so please ensure that yourinstitution (including your legal department) is able and willing to abide by these terms before proceedingwith submission of your application as they will need to be accepted in their entirety.
Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless agenuine conflict exists as between applicable law and the terms of the relevant grant agreement.
Applicant is encouraged to share the core terms with counsel for approval prior to submitting anapplication.
This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.
Payment will only be made to requesting Institution.

Review and Approval Process•Grant requests received in response to a general RFP are reviewed by Pfizer to make final grantdecisions.

Mechanism by which Applicants will be Notified:••

All applicants will be notified via email by the dates noted above.
Applicants may be asked for additional clarification during the review period.

References•

1. WHO fungal priority pathogens list to guide research, development and public health action. Geneva:
World Health Organization; 2022. License: CC BY-NC-SA 3.0 IGO.

4

About Pfizer Global Medical Grants
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives(e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical
need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP)
that provides detail regarding a general area of interest, sets timelines for review and approval, and uses
an internal Pfizer review process to make final grant decisions. Organizations are invited to submit anapplication addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is
responsible for the design, implementation, and conduct of the independent initiative supported by thegrant. Pfizer must not be involved in any aspect of project development, nor the conduct of theindependent education program.

5

Appendix
General RFP Submission Requirements
Applications will be accepted via the online portal listed in the How to Submit section. Project
Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a15-page limit exclusive of references. When uploading your Project Proposal please ensure it
addresses the following sections:Goals and Objectives••

Briefly state the overall goal of the project.
List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

Needs Assessment for the Project•

Include a description of your organization’s needs assessment for this proposed project which may
include a quantitative baseline data summary, initial metrics, or a project starting point (please cite dataon gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

Target Audience•

Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit
from the project outcomes. Describe the overall population size as well as the size of your sample
population.

Project Design and Methods•

Describe the planned project, the educational approach, and the way the planned methods address theestablished need.

Innovation•Explain what measures you have taken to assure that this project is original and does not duplicate otherprojects or materials already developed. Describe how this project builds upon existing work, pilot
projects, or ongoing projects developed either by your institution or other institutions.

Evaluation and Outcomes•

In terms of the metrics used for the needs assessment, describe how your organization will determine if
the gap was addressed for the target group. Identify the sources of data your organization anticipatesusing to make the determination. Describe how your organization is expected to collect and analyze thedata. Explain the method used to control for other factors outside this project (e.g., use of a control groupor comparison with baseline data). Quantify the amount of change expected from this project in terms thetarget audience. Describe how your organization will determine if the target audience was fully engaged
in the project.

Dissemination Plan•

Describe how the project may have extended benefit beyond the grant. Will the teaching materials be
made available to others to use? Will there be tools or resources that are made publicly available beyond
the initial project. Describe how the project outcomes might be broadly disseminated.

Anticipated Project Timeline•

Provide an anticipated timeline for your project including project start/end dates.

6Additional Information•If there is any additional information you feel Pfizer should be aware of concerning the importance of thisproject, please summarize here

Organization Detail•

Describe the attributes of the institutions / organizations / associations that will support and facilitate theexecution of the project and the leadership of the proposed project. Articulate the specific role of eachpartner in the proposed project.

Budget Detail•••••

Please submit your budget in USD.
Please include a budget narrative that describes in greater detail the line items specified in the budget
submitted within the application
While estimating your budget please keep the following items in mind:• Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeuticassets (prescription or non-prescription).
Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Pleaseclick here for details.
General organizational running costs such as legal fees, insurance, heating, and lighting etc. should beincluded in an Institutional Overhead (if required). These costs are not specific to a grant request andtherefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g.,some countries require insurance to be taken out on a per-study basis for clinical research) would beacceptable to be included as line items.

7